Invicta Diagnostic (PC Diagnostics) Ltd. IPO Analysis

Invicta Diagnostics is hitting the market with a ₹28.12 crore IPO right in the middle of India’s diagnostics boom, and it might just be the ticket to riding the wave of rising radiology and pathology testing and data-driven healthcare.

First, let’s cut straight to what’s working and what’s not for Invicta Diagnostics — before diving into their history and numbers.

Now that you’ve seen the snapshot, let’s unpack the full story behind these numbers and understand the business in context.

Industry Outlook- The Healthcare Shift 

India’s healthcare ecosystem isn’t just expanding — it’s leveling up. An ageing population, rising incomes, and steady government support are changing how Indians approach diagnostics. After Covid, people finally saw the value of early detection, and preventive testing became part of everyday healthcare. The diagnostic sector in India has experienced significant growth, with market revenue increasing from Rs. 710 billion in 2020 to Rs. 1,055 billion in 2024 at a CAGR of 10.4%. This growth is expected to continue, reaching Rs. 2,204 billion by 2030 at a CAGR of 13.1% between 2024 and 2030. 

Inside this boom, pathology is the dominant workhorse, holding 62% of the market through routine and specialized tests. But radiology is the faster climber, thanks to its ability to deliver rapid, imaging-based diagnosis. Between 2020–24, radiology outpaced pathology with 11.5% vs 9.7% CAGR, with revenues moving toward ₹407 billion and ₹648 billion respectively by 2024 — signaling a future that's faster, sharper, and more tech-driven.

Powered by Froala Editor

Invicta kicked off in 2021 in the Mumbai Metropolitan Region under the name PC Diagnostics, starting as a focused diagnostic service provider and steadily building trust in its local market. From day one, the company offers pathology and radiology testing services such as imaging, pathology/clinical laboratory and tele radiology to customers. 

Over the next few years, it built out its physical footprint with 7 diagnostic centres and a central laboratory across Mumbai, bringing more testing services under one roof in a reliable and cost-effective way. As operations matured, the leadership began transitioning the business structure, from LLP to private limited and finally to public limited.

What Does The Company Do?

Invicta is a full-stack diagnostic services provider offering ~60 routine and 487 specialized pathology tests, ~96 basic radiology tests, and ~130 advanced imaging services — from X-rays and ultrasounds to CT, MRI, and even PET-CT scans. They serve walk-in patients, doctor referrals, and institutional clients, and also provide home sample collection and teleradiology capabilities for faster reporting.

Their Business Model: Where The Money Comes From

Invicta runs a classic hub-and-spoke diagnostic chain where smaller centres (spokes) collect samples and run basic imaging, while major hubs handle advanced testing for scale, utilization, and cost efficiency. They earn revenue through two primary channels:

• B2C: This is their money-maker and dominates the topline — contributing ~87% of total revenue in FY25, thanks to higher pricing and better margins on individual tests.
  
  

• B2B: The remaining share comes from hospitals, clinics, medical partners, and corporate check-ups — stable volumes, lower margins.

On top of that, advanced radiology is a serious revenue driver, bringing significantly higher ticket sizes than basic tests, which is why radiology revenue is meaningfully higher than pathology.

Operational Momentum: Invicta’s Scale-Up Story in Numbers

Invicta handled more than double the number of patients and tests in FY25 compared to FY24, which shows strong demand and better use of its centres. They reduced one diagnostic centre but increased the number of patients and tests performed—meaning more efficient use of existing centres. 

The share of institutional business grew from 6% to 13%, which helps reduce dependence on walk-in customers, but usually brings in lower pricing. 

At the same time, the average revenue earned per test dropped, meaning they might be doing more tests per customer but at slightly lower rates. Radiology, especially advanced scans like MRI and CT— continues to be the company’s biggest money-maker, while pathology is growing but still small in comparison.

Powered by Froala Editor

The company has one flagship centre in Thane, which serves as the main hub, equipped for a wide range of diagnostic services, including pathology specimen collection and advanced radiology tests. 

3 Hub centres with similarly equipped to provide diagnostic services, and 

3 Spoke centres offer essential pathology tests and basic radiology services, including one co-located with our centralized laboratory for convenience. 

The company operates relatively few self-owned centres, which limits its direct brand visibility among patients. In a market where consumer trust is closely tied to brand familiarity, this places Invicta at a disadvantage versus larger diagnostic chains that have already built strong, recognizable brands across the Mumbai region.

They are planning to expand their hub centres up to 5  in Maharashtra with special focus on the areas such as Kalyan, Vasai-Virar region, Malad – Kandivali and Akola. 

Revenue Breakdown: Where Does Revenue Come From?

Radiology has historically been Invicta’s revenue engine — contributing 88–98% of total diagnostic income over the last three years. Pathology, meanwhile, is still a small slice of the pie, but the company is now actively trying to grow this stream. 

Here’s the thing — pathology brings in far lower revenue per test (around ₹250 on average), which is a fraction of what advanced radiology earns per scan. While expanding pathology may help diversify their service mix and bring more patient traffic, it risks dragging down revenue-per-test and overall margins. 

In short, Invicta’s shift toward building a larger pathology base looks strategic from a scale perspective, but financially, it’s a margin-moderating move rather than a profit-boosting one.

Powered by Froala Editor

Institutional revenue has grown from ~₹116 lakh to ~₹399 lakh, showing the company is building more hospital and clinic partnerships. But here’s the thing — B2C revenue is still the main driver at ~87% of total revenue, meaning Invicta remains heavily dependent on individual walk-in customers. While institutional growth adds stability, it also comes with thinner pricing and lower margins compared to consumer diagnostics. So yes, the revenue base is diversifying, but profitability could feel pressure if the institutional mix keeps rising.

Peer Comparison 

The company receives competition from big players like Krsnaa Diagnostics Limited and Vijaya Diagnostic Centre Ltd., which are established leading players in the industry. 

Although they have taken them as their peers; they are not comparable by apple on apple basis.

We have taken chandan healthcare limited and star Imaging and Path Lab Ltd due to their size and services provided.

Invicta and Star look similar in margin profile — both run profitable, radiology-led models with strong ROEs. Star, however, operates at a far larger scale and converts that into slightly better EBITDA and PAT margins, which suggests more mature cost efficiency. 

Invicta’s P/E is a bit higher than Star’s, meaning it’s being priced with more growth expectation but also more risk given its smaller footprint. 

In short: Star is the more proven operator today, while Invicta represents a smaller, earlier-stage player with upside but also execution risk.

Powered by Froala Editor

The Funds raised by the company will be used to:

• Fund capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra

• General Corporate purposes 

Final Words

Looking through LMVT:

Leadership: Strong promoter-led execution in radiology, but leadership depth is narrow and still founder-centric.

Moat: The only edge is 24×7 operations — useful, but replicable. In a crowded diagnostics market with big brands already entrenched, this doesn’t translate into lasting advantage.

Valuation: The IPO isn’t cheap — it prices in future growth that hasn’t yet expanded beyond Mumbai. Current margins are boosted by radiology, but as pathology scales with low ARPT, profitability can get squeezed.

Tailwinds: Diagnostics in India is growing, no doubt. But stronger players with bigger networks and brand visibility capture the upside much faster.

Bottom line: Invicta runs a solid regional operation but doesn’t yet have a defensible moat or scaled presence. Investing here isn’t a safe-sector bet — it’s a higher-risk early-stage bet that depends heavily on execution and expansion.

Powered by Froala Editor